DDInter241 DDInter899
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239]
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Bromfenac {u} (Compound) resembles {v} (Compound) Balsalazide
Bromfenac {u} (Compound) resembles {v} (Compound) Suprofen
Bromfenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Bromfenac {u} (Compound) binds {v} (Gene) PTGS2
Bromfenac {u} (Compound) upregulates {v} (Gene) DDX10
Bromfenac {u} (Compound) is included by {v} (Pharmacologic Class) Cyclooxygenase Inhibitors
Bromfenac {u} (Compound) downregulates {v} (Gene) IFRD2
Bromfenac {u} (Compound) causes {v} (Side Effect) Eye pain
Bromfenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Bromfenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Bromfenac (Compound) resembles Balsalazide (Compound)
Bromfenac (Compound) resembles Suprofen (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Bromfenac (Compound) binds PTGS2 (Gene)
Bromfenac (Compound) upregulates DDX10 (Gene)
Bromfenac (Compound) is included by Cyclooxygenase Inhibitors (Pharmacologic Class)
Bromfenac (Compound) downregulates IFRD2 (Gene)
Bromfenac (Compound) causes Eye pain (Side Effect)
Bromfenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Bromfenac may cause a minor interaction that can limit clinical effects when taken with Linaclotide